Kristyna Kolarikova
Research Subjects
Kristyna Kolarikova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Martin Prochazka
University Hospital, Olomouc, Czech Republic
2 shared publications - Radek Vodicka
Department of Clinical Genetics, University Hospital Olomouc, Olomouc, Czech Republic
2 shared publications - Radek Vrtel
Ustav lékarské genetiky a fetální medicíny FN a UP, Olomouc
2 shared publications - Júlia Štellmachová
FN Olomouc, Ustav lekarske genetiky, I P Pavlova 272 10, Olomouc 77900, Czech Republic
1 shared publication - Kateřina Menšíková
Department of Neurology and Clinical Neuroscience Center, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
1 shared publication - Mária Janíková
FN Olomouc, Ustav lekarske genetiky, I P Pavlova 272 10, Olomouc 77900, Czech Republic
1 shared publication
Latest Publications
- 27 June 2022
- Published by Care Comm in Česká gynekologie
- Vol. 87 (3) , 211-216
Ovarian tumors and genetic predisposition
Objective: Summary of knowledge in the field of ovarian cancer and genetic predisposition. Results: Ovarian tumors are usually dia gnosed at advanced stages of the disease and the prognosis for these patients is generally poor. The 5-year overall survival rate, regardless of the histopathological type of tumor, is around 44%. Germline mutations causing hereditary tumor syndromes are predominantly involved in the development of epithelial ovarian tumors. The most common is hereditary breast and ovarian cancer syndrome, which is caused by germline mutations in the tumor suppressor genes BRCA1 and BRCA2. Several other tumor suppressor genes and oncogenes are known to be associated with ovarian tumors and cause other types of tumor syndromes. Inherited tumor syndromes include Lynch syndrome, Peutz-Jegers syndrome, Gorlin syndrome, Li-Fraumeni syndrome and others. The indication for genetic examination of germline mutations is given by a clinical geneticist on the basis of the recommendation of the attending physician. At present, every ovarian tumor, primary peritoneal tumor and tube tumor dia gnosed at any age is indicated for genetic testing. Conclusion: Early identification of genes for hereditary cancer syndromes, thanks to rapidly developing molecular genetic methods, is an important step towards personalized treatment of ovarian cancer and preventive measures in families at risk. It is also important to note that a negative molecular genetic test result does not exclude genetic risk.
- 27 June 2022
- Published by Care Comm in Česká gynekologie
- Vol. 87 (3) , 211-216
Ovarian tumors and genetic predisposition
Objective: Summary of knowledge in the field of ovarian cancer and genetic predisposition. Results: Ovarian tumors are usually dia gnosed at advanced stages of the disease and the prognosis for these patients is generally poor. The 5-year overall survival rate, regardless of the histopathological type of tumor, is around 44%. Germline mutations causing hereditary tumor syndromes are predominantly involved in the development of epithelial ovarian tumors. The most common is hereditary breast and ovarian cancer syndrome, which is caused by germline mutations in the tumor suppressor genes BRCA1 and BRCA2. Several other tumor suppressor genes and oncogenes are known to be associated with ovarian tumors and cause other types of tumor syndromes. Inherited tumor syndromes include Lynch syndrome, Peutz-Jegers syndrome, Gorlin syndrome, Li-Fraumeni syndrome and others. The indication for genetic examination of germline mutations is given by a clinical geneticist on the basis of the recommendation of the attending physician. At present, every ovarian tumor, primary peritoneal tumor and tube tumor dia gnosed at any age is indicated for genetic testing. Conclusion: Early identification of genes for hereditary cancer syndromes, thanks to rapidly developing molecular genetic methods, is an important step towards personalized treatment of ovarian cancer and preventive measures in families at risk. It is also important to note that a negative molecular genetic test result does not exclude genetic risk.